FDA approves 1st neurological treatment for Type 3 Gaucher disease

The FDA has approved Infilbray (venglustat) tablets, the first treatment for neurological symptoms of Type 3 Gaucher disease. The drug is approved for adults and pediatric patients weighing at least 15 kilograms (approximately 33 pounds), according to a Nov. 18 FDA news release. Infilbray crosses the blood-brain barrier and works as a glucosylceramide synthase inhibitor. […] The post FDA approves 1st neurological treatment for Type 3 Gaucher disease appeared first on Becker's Hospital...

Original Source

Read the full article at Beckershospitalreview →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.